A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study.
J Bennouna, T André, E Martin, C Cremolini, S Gill, T Asmis, P Kavan, E Mitry, S Hiret, L Mineur, P Artru, C Perret, O Bouché, Y Touchefeu, B Goldenberg, O Dupuis, S Lonardi, B Chibaudel, H Castanié, C Coutzac, L Bauguion, E Guardiola, A Benmaziane, J Barrière, E Chen, V Simmet, G Allegrini, F Marmorino, V Pezzella, L Monard, L Campion, C O'Callaghan, J Taieb
Ann Oncol S0923-7534(26)06886-9
摘要
摘要
BACKGROUND: Patients with pT4 and/or pN2 stage III colon cancer remain at high risk of recurrence despite oxaliplatin-based adjuvant chemotherapy. We evaluated whether intensification with modified FOLFIRINOX improved outcomes compared with modified FOLFOX6. PATIENTS AND METHODS: In this international, academic, open-label, randomised phase III trial conducted by Partenariat de Recherche en Oncologie DIGEstive (PRODIGE) in France, Canadian Cancer Trials Group in Canada, and Gruppo Oncologico del Nord Ovest in Italy, patients with stage III colon adenocarcinoma after R0 resection presenting T4 and/or N2 were randomly assigned (1 : 1) to receive mFOLFIRINOX or mFOLFOX6 every 2 weeks for 12 cycles. The primary endpoint was 3-year disease-free survival (DFS) in the intention-to-treat population. RESULTS: Between May 2017 and June 2023, 795 patients were assigned to mFOLFIRINOX (n = 398) or mFOLFOX6 (n = 397). Median age was 59 years (range 19-75); 39.7% were women, 52.8% had pT4 disease, 72.2% had pN2 disease, and 25.3% had both. At a median follow-up of 55 months (interquartile range 42.6-65.9), 284 DFS events had occurred: 146 with mFOLFIRINOX and 138 with mFOLFOX6. Three-year DFS was 65.6% versus 66.3%, respectively [hazard ratio (HR) 1.07, 95% confidence interval (CI) 0.84-1.36; P = 0.61). Although overall survival (OS) data remain immature, 3-year OS was 91.2% versus 86.7% (HR 0.85, 95% CI 0.61-1.21; P = 0.37); no significant treatment-by-subgroup interaction was observed. Grade ≥3 adverse events occurred in 62.2% and 62.1% of patients, respectively. Grade ≥3 diarrhoea (15.6% versus 3.8%) and fatigue (7.3% versus 1.8%) were more frequent with mFOLFIRINOX, whereas grade ≥3 neutropenia was less frequent (18.0% versus 23.9%). Granulocyte colony-stimulating factor use was 37.8% versus 19.1%. CONCLUSION: Adjuvant mFOLFIRINOX triplet chemotherapy did not improve DFS compared with standard doublet mFOLFOX6 in patients with high-risk stage III colon cancer. These findings do not support empirical chemotherapy intensification and highlight the need for novel adjuvant strategies.
KM 提取结果
0 个 Figure · 0 个 KM 面板